Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher‐risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes-Reference-Cited by-同舟云学术

Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher‐risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes

Published:2020-06-26 Issue:4 Volume:38 Page:541-553
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Papadopoulos Vasileios¹,Diamantopoulos Panagiotis T.²^ORCID,Papageorgiou Sotirios G.³^ORCID,Papoutselis Menelaos¹,Vrachiolias George¹,Pappa Vassiliki³^ORCID,Galanopoulos Athanasios G.⁴,Vassilakopoulos Theodoros P.⁵,Hatzimichael Eleftheria⁶,Zikos Panagiotis⁷,Papadaki Helen A.⁸,Bouchla Anthi³,Panayiotidis Panayiotis⁹,Megalakaki Aekaterini¹⁰,Papaioannou Maria¹¹,Liapis Konstantinos¹,Dryllis George²,Tsokanas Dimitris¹²,Kourakli Alexandra¹²,Symeonidis Argiris¹²,Viniou Nora‐Athina²,Kotsianidis Ioannis¹^ORCID

Affiliation:

1. Department of Hematology Democritus University of Thrace Medical School Alexandroupolis Greece

2. First Department of Internal Medicine National and Kapodistrian University of Athens Athens Greece

3. Second Department of Internal Medicine, Hematology Unit Attikon University General Hospital Athens Greece

4. Department of Clinical Hematology G. Gennimatas Hospital Athens Greece

5. Department of Hematology, Laikon General Hospital National and Kapodistrian University of Athens Athens Greece

6. Department of Hematology University Hospital of Ioannina Ioannina Greece

7. Department of Hematology General Hospital of Patras “Agios Andreas” Patras Greece

8. Department of Hematology University General Hospital of Heraklion Heraklion Greece

9. First Propaedeutic Department of Internal Medicine National and Kapodistrian University of Athens Athens Greece

10. Department of Hematology “Metaxa” Piraeus Cancer Hospital Piraeus Greece

11. Department of Hematology Aristotle University of Thessaloniki, AHEPA Hospital Thessaloniki Greece

12. Department of Internal Medicine University Hospital of Patras Rio Greece

Funder

Genesis Pharma

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2756

Reference35 articles.

1. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome

2. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome

3. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

4. Azacitidine in the ‘real-world’: an evaluation of 1101 higher-risk myelodysplastic syndrome/low blast count acute myeloid leukaemia patients in Ontario, Canada

5. Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comorbidities and frailty predict outcome of patients with myelodysplastic syndromes. Should we integrate them in novel prognostic scoring systems?;Journal of Geriatric Oncology;2021-09

2. Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine;Epigenomics;2021-07

3. Factors affecting response to 5-azacytidine and prognosis of myelodysplastic syndrome. Is long-term survival a realistic goal?;Leukemia Research;2021-04